Cargando…

Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain

Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer Albiach, Carlos, Villegas Estévez, Francisco, López Alarcón, Mª Dolores, de Madariaga, María, Carregal, Alfonso, Arranz, Javier, Trinidad Martín-Arroyo, José M, Jiménez López, Antonio Javier, Sanz Yagüe, Almudena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636433/
https://www.ncbi.nlm.nih.gov/pubmed/31372030
http://dx.doi.org/10.2147/JPR.S194881
_version_ 1783436060845408256
author Ferrer Albiach, Carlos
Villegas Estévez, Francisco
López Alarcón, Mª Dolores
de Madariaga, María
Carregal, Alfonso
Arranz, Javier
Trinidad Martín-Arroyo, José M
Jiménez López, Antonio Javier
Sanz Yagüe, Almudena
author_facet Ferrer Albiach, Carlos
Villegas Estévez, Francisco
López Alarcón, Mª Dolores
de Madariaga, María
Carregal, Alfonso
Arranz, Javier
Trinidad Martín-Arroyo, José M
Jiménez López, Antonio Javier
Sanz Yagüe, Almudena
author_sort Ferrer Albiach, Carlos
collection PubMed
description Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians’ satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion. Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient’s perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p<0.01). Furthermore, most physicians (71.8%) were satisfied with the BTcP therapy prescribed. Conclusions: Our results demonstrate the need for routine assessment of quality of life in patients with bone BTcP. These findings also underscore the necessity for a multidisciplinary therapeutic strategy for breakthrough pain in clinical practice in Spain.
format Online
Article
Text
id pubmed-6636433
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66364332019-08-01 Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain Ferrer Albiach, Carlos Villegas Estévez, Francisco López Alarcón, Mª Dolores de Madariaga, María Carregal, Alfonso Arranz, Javier Trinidad Martín-Arroyo, José M Jiménez López, Antonio Javier Sanz Yagüe, Almudena J Pain Res Original Research Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians’ satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion. Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient’s perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p<0.01). Furthermore, most physicians (71.8%) were satisfied with the BTcP therapy prescribed. Conclusions: Our results demonstrate the need for routine assessment of quality of life in patients with bone BTcP. These findings also underscore the necessity for a multidisciplinary therapeutic strategy for breakthrough pain in clinical practice in Spain. Dove 2019-07-12 /pmc/articles/PMC6636433/ /pubmed/31372030 http://dx.doi.org/10.2147/JPR.S194881 Text en © 2019 Ferrer Albiach et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ferrer Albiach, Carlos
Villegas Estévez, Francisco
López Alarcón, Mª Dolores
de Madariaga, María
Carregal, Alfonso
Arranz, Javier
Trinidad Martín-Arroyo, José M
Jiménez López, Antonio Javier
Sanz Yagüe, Almudena
Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title_full Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title_fullStr Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title_full_unstemmed Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title_short Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
title_sort real-life management of patients with breakthrough cancer pain caused by bone metastases in spain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636433/
https://www.ncbi.nlm.nih.gov/pubmed/31372030
http://dx.doi.org/10.2147/JPR.S194881
work_keys_str_mv AT ferreralbiachcarlos reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT villegasestevezfrancisco reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT lopezalarconmadolores reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT demadariagamaria reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT carregalalfonso reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT arranzjavier reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT trinidadmartinarroyojosem reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT jimenezlopezantoniojavier reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain
AT sanzyaguealmudena reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain